US 12,441,711 B2
Compounds and their use for treatment of hemoglobinopathies
Thomas J. Cummins, San Diego, CA (US); Scott Arne Johnson, San Diego, CA (US); Hannah L. Powers, San Diego, CA (US); and Giorgio Tamo, Biel (CH)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed on Jan. 17, 2025, as Appl. No. 19/029,638.
Application 19/029,638 is a continuation of application No. PCT/US2023/078600, filed on Nov. 3, 2023.
Claims priority of provisional application 63/422,847, filed on Nov. 4, 2022.
Prior Publication US 2025/0163025 A1, May 22, 2025
Int. Cl. C07D 401/14 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/4709 (2006.01); A61K 45/06 (2006.01); C07D 401/04 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 45/06 (2013.01); C07D 401/04 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01)] 19 Claims
 
1. A compound according to Formula (III):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein:
Q″ is H or CH3,
R12 is

OG Complex Work Unit Chemistry
wherein
Q3 is selected from H, Cl, or F;
Q4 is selected from H, CH3, or CH(F)2;
Q5 is selected from H, CH3, or OCH3; and
Q6 is selected from H or F.